Key facts
- This page summarizes Francois Lebel's Form 4 filing for SPECTRUM PHARMACEUTICALS INC.
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 23 Jun 2022, 20:24.
Francois Lebel - 21 Jun 2022 Form 4 Insider Report for SPECTRUM PHARMACEUTICALS INC
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 21 Jun 2022
- Net transaction value
- -$10,507
- SEC form
- 4
- Accepted by SEC
- 23 Jun 2022, 20:24:52 UTC
- Prior SEC filing
- 05 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Keith M. McGahan, attorney-in-fact for Francois Lebel
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Francois Lebel filed Form 4 for SPECTRUM PHARMACEUTICALS INC on 23 Jun 2022.
Change
- Previous filing in this sequence was filed on 05 Apr 2022.
- Current net transaction value: -$10,507.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPPI
transaction
Common Stock, $0.001 par value
Award
- Transaction value
- $0
- Shares
- +405,040
- Change %
- +160%
- Price
- $0.000000
- Shares after
- 657,553
- Date
- 21 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
SPPI
transaction
Common Stock, $0.001 par value
Sale
- Transaction value
- $4,913
- Shares
- -6,096
- Change %
- -0.93%
- Price
- $0.8060
- Shares after
- 651,457
- Date
- 22 Jun 2022
- Ownership
- Direct
- Footnotes
- F2
SPPI
transaction
Common Stock, $0.001 par value
Sale
- Transaction value
- $5,594
- Shares
- -6,667
- Change %
- -1%
- Price
- $0.8390
- Shares after
- 644,790
- Date
- 23 Jun 2022
- Ownership
- Direct
- Footnotes
- F2
SPPI
holding
Common Stock, $0.001 par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,226
- Date
- 21 Jun 2022
- Ownership
- By 401(k) plan
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPPI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,488,940
- Change %
- Price
- $0.000000
- Shares after
- 1,488,940
- Date
- 21 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,488,940
- Exercise price
- $0.6300
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The restricted stock unit grant was approved by Spectrum Pharmaceuticals, Inc.'s ("Spectrum") board of directors on January 27, 2022, subject to stockholder approval of the Amended and Restated 2018 Long-Term Incentive Plan (the "Plan") under which the restricted stock unit was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
Footnote F2
All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer.
Footnote F3
The option grant was approved by Spectrum's board of directors on January 27, 2022, subject to stockholder approval of the Plan under which the option was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
Footnote F4
One third of the aggregate amount of option shares shall vest on each of January 27, 2023, 2024 and 2025, respectively.